Lumiracoxib

Lumiracoxib is a selective inhibitor of COX-2 with IC50 values of 0.13 and 67 µM for COX-2 and COX-1, respectively, in isolated human whole blood. It reduces increases in the levels of prostaglandin E2 (PGE2, Cay-14010) induced by IL-1beta in human dermal fibroblasts (IC50 = 0.14 µM), as well as in LPS-stimulated RAW 264.7 cells when used at concentrations ranging from 1 to 100 µM., Lumiracoxib (3 and 10 mg/kg) also decreases LPS-induced increases in the levels of PGE2 in a rat model of air pouch inflammation. It reduces M. tuberculosis-induced increases in hind paw volume and the radiological and histopathological severity of arthritic lesions in a rat model of chronic arthritis when administered at a dose of 2 mg/kg.Formal Name: 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl-benzeneacetic acid. CAS Number: 220991-20-8. Synonyms: COX 189. Molecular Formula: C15H13ClFNO2. Formula Weight: 293.7. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 30 mg/ml, DMSO: 30 mg/ml, DMSO:PBS (pH 7.2) (1:4): 0.20 mg/ml. lambdamax: 274 nm. SMILES: CC1=CC(CC(O)=O)=C(NC2=C(Cl)C=CC=C2F)C=C1. InChi Code: InChI=1S/C15H13ClFNO2/c1-9-5-6-13(10(7-9)8-14(19)20)18-15-11(16)3-2-4-12(15)17/h2-7,18H,8H2,1H3,(H,19,20). InChi Key: KHPKQFYUPIUARC-UHFFFAOYSA-N.